ArriVent BioPharma, Inc. (AVBP): Shareholders' Equity
$307.22M
As of 2025-12-31
$366.84M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $307.22M | +19.2% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $257.65M | n/m | 2026-03-05, Balance as of period end |
| 2023-12-31 | -$153.19M | n/a | 2025-03-03, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | 2025-12-31 | $307.22M | +19.2% |
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | $305.26M | +85.3% |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $277.22M | -40.2% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $303.13M | -47.0% |
| Liquidia Corp (LQDA) | 2025-12-31 | $44.75M | -43.6% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $114.26M | -55.5% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $280.47M | -42.4% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $248.20M | -35.2% |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $306.83M | n/m |
Compare AVBP, AMLX, RCKT, KROS side by side · Screen every company in Pharmaceutical Preparations ↗